New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
14:36 EDTAKRXAkorn sees 2013 gross margins 54%-56%
Overall gross margins for 2013 are expected to be in the range of 54%-56% as a result of growth from lower margin new products that are either partnered with shared economics, in-licensed or are contract manufactured for Akorn. The vast majority of Akorn's active pipeline will be manufactured by Akorn with no partnering or shared economics and as a result are expected to have significantly higher margins than the products contributing to growth in 2013. Additionally, we expect improvement in the margins on our more competitive products once we achieve U.S. FDA approval of our Indian manufacturing site.
News For AKRX From The Last 14 Days
Check below for free stories on AKRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
17:55 EDTAKRXRepligen to replace Hi-Tech Pharmacal in S&P 600 as of 4/17
Subscribe for More Information
April 14, 2014
19:01 EDTAKRXAkorn gets FTC clearance for Hi-Tech Pharmacal deal
Akorn (AKRX) announced that the U.S. FTC has voted to approve Akornís acquisition of Hi-Tech Pharmacal (HITK). The unanimous vote in support of the transactions follows Akornís agreement to a proposed consent order requiring divestiture of certain products as a condition to obtaining FTC approval. The parties have now obtained all regulatory approvals required to consummate the acquisition, and intend to close by the end of this week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use